Expres2ion Biotechnologies Aps

Walter and Eliza Hall Institute of Medical Research

Expres2ion Biotechnologies

Willem Adriaan De Jongh

Peter Birk Rasmussen

Alan E Cowman

Vladyslav Soroka

Charlotte Dyring

Teit Max Moscote Søgaard

Stine Broch Clemmensen

Teit Max Moscote Sogaard

Julie Healer

Thomas Dan Jorgensen

Helene Lykkegaard

Disclosed are immunization antigens that have been glyco-engineered to include non-native glycosylation patterns with a view to enhance their properties as antigens for use in such areas as vaccination and antibody production. Also disclosed are to means and methods for producing the glycomodified antigens as well of methods and uses of the glycomodified antigens.

Glyco-engineered immunization antigens

The present description relates to malaria vaccines comprising(Pf) polypeptide complexes and methods of producing the same. The Pf polypeptides in complexes or in a partially complexed arrangement may comprise two or more of the following polypeptides: PfRipr, PfCyrPa and PfRh5.cells and expression vectors are also described.

Malaria vaccine and methods for producing same

Disclosed is a DNA polynucleotide comprising a nucleic acid sequence having promoter activity in aS2 cell, where said nucleic acid sequence is selected from (i) a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO: 37, or SEQ ID NO: 68 with or without flanking restriction site sequences at either terminus; (ii) a functional nucleotide sequence with a sequence identity of at least 80% to any one sequence of (i); (iii) a nucleotide which is a functional fragment of at least 6 contiguous nucleotides of any one sequence of (i) or (ii); (iv) a functional nucleotide sequence with a sequence identity of at least 80% to said functional fragment of (iii); (v) a first chimeric nucleotide sequence comprising two or more sequences of any one sequence of (i), (ii), (iii) and (iv), and (vi) a second chimeric nucleotide sequence, comprising at least 6 nucleotides and including consecutive nucleotide stretches from at least 2 nucleotide sequences of (iii) and/or (iv), where each of said consecutive stretches alone does not have promoter activity in aS2 cell. Also disclosed are vectors and cells comprising the polynucleotide and a method for producing a polypeptide of interest by use of the polynucleotide.

Protein expression system

Growing community of inventors

Valby, Denmark

Willem Adriaan De Jongh